Pharma in silica inc. announces today the closing of a $ 2,000,000 funding to continue the development of OpPacli™, an original nanomedicine developed to provide patients suffering from certain solid cancers with a well-tolerated and more efficient chemotherapy.
The Board of Directors of Pharma in silica Laboratories has expanded to seven members with the addition of Ms. Isabelle Tremblay, MBA.
Pharma in silica acquires ownership of three three pending patent families that form the basis of its technology OpKemo technology.
Pharma in silica is initiating the preclinical study of its product candidate OpPacli™ (optimized paclitaxel) against non-small cell lung cancer (NSCLC).
Myriam Laprise-Pelletier, PhD, previously Translational Researcher at Pharma in Silica and Research Professional at the CHU de Québec/Université Laval, has been promoted to Scientific Coordinator.
The development of two original biodistribution methods in mouse models and the development of the second generation of the OpPacli™ (optimized paclitaxel) prototype are among the main results of the program.
July 27, 2020 – Big day for Pharma in silica: their own laboratory is inaugurated. The preclinical-stage company develops a…
Québec City, February 3rd, 2020 — The staff and shareholders of Pharma in silica inc. express their gratitude to the…
Québec City, September 23, 2019 – Pharma in silica inc. announces today the addition of mister Bertrand Bolduc, pharmacist and…
QUÉBEC City, August 30, 2019 – Pharma in silica inc. announces today the closing of a start-up funding of 1,4…